Home / Health / Alzheimer's Blood Tests Arrive in China
Alzheimer's Blood Tests Arrive in China
14 Jan
Summary
- BGI Genomics and Roche Diagnostics introduced Alzheimer's blood tests in China.
- These tests aim to simplify diagnosis and monitoring for patients.
- Blood tests offer a quicker, easier alternative to PET scans or spinal taps.
New advancements in Alzheimer's disease diagnosis are now available in China, with BGI Genomics and Roche Diagnostics rolling out innovative blood tests. These tests are designed to provide patients with more accessible options for evaluating the progression and risk of the brain-wasting condition. This development promises to significantly speed up the diagnostic process, potentially leading to earlier intervention and treatment.
BGI Genomics is utilizing a blood test as an auxiliary tool in key cities like Guangzhou, Qingdao, Shenzhen, and Wuhan. Concurrently, Roche's test, which measures the pTau181 protein linked to Alzheimer's, has been introduced in Boao, Hainan province. These newer methods offer a less invasive and more convenient alternative to traditional diagnostic procedures.
Compared to costly PET scans or uncomfortable spinal taps, blood tests offer a more straightforward pathway. While BGI Genomics notes their test is not standalone evidence for diagnosis, doctors find it beneficial for early screening. Roche highlights that a negative result can help patients avoid unnecessary further investigations, guiding them toward appropriate care pathways.
